Information
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors concerning
Original sourceAI Summary
Kirby McInerney LLP is investigating Soleno for possible federal securities law violations. Vykat XR faced scrutiny over safety, leading to significant share price drops. CEO noted disruptions in Vykat XR's launch due to adverse events linked to the product. Shares fell 26.59% after earnings call revealed higher discontinuation rates. Investors are urged to reach out for more information about their rights.
Sentiment Rationale
The investigation and adverse reports on Vykat XR indicate potential long-term operational and reputational risks, similar to past cases where legal actions severely impacted stock prices, as seen with other pharmaceutical companies facing product safety issues.
Trading Thesis
Immediate investor sentiment is likely to worsen as security investigations unfold, similar to historical cases where initial reports prompted quick stock declines.
Market-Moving
- Kirby McInerney LLP is investigating Soleno for possible federal securities law violations.
- Vykat XR faced scrutiny over safety, leading to significant share price drops.
- CEO noted disruptions in Vykat XR's launch due to adverse events linked to the product.
Key Facts
- Kirby McInerney LLP is investigating Soleno for possible federal securities law violations.
- Vykat XR faced scrutiny over safety, leading to significant share price drops.
- CEO noted disruptions in Vykat XR's launch due to adverse events linked to the product.
- Shares fell 26.59% after earnings call revealed higher discontinuation rates.
- Investors are urged to reach out for more information about their rights.
Companies Mentioned
- SLNO (SLNO)
- VRTX (VRTX)
- PTCT (PTCT)
- INCY (INCY)
- ALNY (ALNY)
Legal
The gravity of the legal investigation surrounding Soleno has strong implications for investor sentiment and stock valuation, reflective of historic trends in the market.
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On August 15, 2025, Scorpion Capital published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. On this news, the price of Soleno shares declined by $5.73 per share, or approximately 7.41%, from $77.36 per share on August 14, 2025 to close at $71.64 on August 15, 2025.
Then on November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of Vykat XR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025. Soleno's Chief Executive Officer disclosed during the call that Soleno "did see a disruption in our [Vykat XR] launch trajectory in the wake of a short seller report that was released in mid-August [i.e, the Scorpion Capital report], mostly in the form of a lower number of start forms and increased discontinuations for non-serious adverse events. On this news, the price of Soleno shares declined by $16.98 per share, or approximately 26.59%, from $63.85 per share on November 4, 2025 to close at $46.87 on November 5, 2025.
What Should I Do?
If you purchased or otherwise acquired Soleno securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com
